The present disclosure relates generally to medical treatment systems for treating tissue sites and processing fluids. More particularly, but not by way of limitation, the present disclosure relates to a canister having a device for the removal of liquid from a fluid.
Clinical studies and practice have shown that reducing pressure in proximity to a tissue site can augment and accelerate growth of new tissue at the tissue site. The applications of this phenomenon are numerous, but is has proven particularly advantageous for treating wounds. Regardless of the etiology of a wound, whether trauma, surgery, or another cause, proper care of the wound is important to the outcome. Treatment of wounds with reduced pressure may be commonly referred to as “reduced-pressure wound therapy,” but is also known by other names, including “negative-pressure therapy,” “negative pressure wound therapy,” and “vacuum therapy,” for example. Reduced-pressure therapy may provide a number of benefits, including migration of epithelial and subcutaneous tissues, improved blood flow, and micro-deformation of tissue at a wound site. Together, these benefits can increase development of granulation tissue and reduce healing times.
While the clinical benefits of reduced-pressure therapy are widely known, the cost and complexity of reduced-pressure therapy can be a limiting factor in its application, and the development and operation of reduced-pressure systems, components, and processes continues to present significant challenges to manufacturers, healthcare providers, and patients.
According to an illustrative embodiment, a system for treating a tissue site with reduced pressure is described. The system may include a dressing adapted to be placed adjacent to the tissue site and a canister having a fluid reservoir adapted to be fluidly coupled to the dressing. A moisture trap may be fluidly coupled to the fluid reservoir. The moisture trap may include a barrier and a sump adapted to receive condensation from the barrier. A reduced-pressure source may be adapted to be fluidly coupled to the moisture trap. The barrier may include a hydrophilic surface and define an indirect fluid path between the fluid reservoir and the reduced-pressure source.
According to another illustrative embodiment, a moisture trap for removing liquid from fluids from a tissue site treated with reduced pressure is described. The moisture trap may include a barrier adapted to be fluidly coupled to and define an indirect fluid path between a fluid reservoir and a reduced-pressure source. The barrier may have a hydrophilic surface. The moisture trap also may include a sump adapted to receive condensation from the barrier.
According to yet another illustrative embodiment, a method for treating a tissue site with reduced pressure is described. A reduced-pressure dressing may be disposed adjacent to the tissue site and fluidly couple a reduced-pressure source to the reduced-pressure dressing. Reduced pressure can be supplied to the reduced-pressure dressing with the reduced-pressure source, and fluid may be drawn from the tissue site with the reduced-pressure dressing and the reduced-pressure source. The fluid may be collected in a fluid reservoir in a canister fluidly coupled between the reduced-pressure dressing and the reduced-pressure source. The fluid may be moved through an indirect fluid path that may be fluidly coupled between the canister and the reduced-pressure source. The indirect fluid path may be formed by a barrier having a hydrophilic surface to condense liquids from the fluids. The condensed liquid may be channeled from the hydrophilic surface to a sump to store the condensed liquids.
According to still another illustrative embodiment, a method of manufacturing a moisture trap for removing liquid from fluids from a tissue site treated with reduced pressure is described. A barrier may be adapted to be fluidly coupled between a fluid reservoir and a reduced-pressure source, the barrier having a hydrophilic surface. The barrier may be positioned between the fluid reservoir and the reduced-pressure source to define an indirect fluid path. A sump may be provided and adapted to receive condensation from the barrier.
Other aspects, features, and advantages of the illustrative embodiments will become apparent with reference to the drawings and detailed description that follow.
New and useful systems, methods, and apparatuses for removing liquid from fluid drawn from a tissue site in a reduced-pressure therapy environment are set forth in the appended claims. Objectives, advantages, and a preferred mode of making and using the systems, methods, and apparatuses may be understood best by reference to the following detailed description in conjunction with the accompanying drawings. The description provides information that enables a person skilled in the art to make and use the claimed subject matter, but may omit certain details already well-known in the art. Moreover, descriptions of various alternatives using terms such as “or” do not necessarily require mutual exclusivity unless clearly required by the context, and reference to “an” item generally refers to one or more of those items. The claimed subject matter may also encompass alternative embodiments, variations, and equivalents not specifically described in detail. The following detailed description should therefore be taken as illustrative and not limiting.
The example embodiments may also be described herein in the context of reduced-pressure therapy applications, but many of the features and advantages are readily applicable to other environments and industries. Spatial relationships between various elements or to the spatial orientation of various elements may be described as depicted in the attached drawings. In general, such relationships or orientations assume a frame of reference consistent with or relative to a patient in a position to receive reduced-pressure therapy. However, as should be recognized by those skilled in the art, this frame of reference is merely a descriptive expedient rather than a strict prescription.
The term “tissue site” in this context broadly refers to a wound or defect located on or within tissue, including but not limited to, bone tissue, adipose tissue, muscle tissue, neural tissue, dermal tissue, vascular tissue, connective tissue, cartilage, tendons, or ligaments. A wound may include chronic, acute, traumatic, subacute, and dehisced wounds, partial-thickness burns, ulcers (such as diabetic, pressure, or venous insufficiency ulcers), flaps, and grafts, for example. The term “tissue site” may also refer to areas of any tissue that are not necessarily wounded or defective, but are instead areas in which it may be desirable to add or promote the growth of additional tissue. For example, reduced pressure may be used in certain tissue areas to grow additional tissue that may be harvested and transplanted to another tissue location.
In general, components of the therapy system 100 may be coupled directly or indirectly. For example, reduced-pressure source 108 may be directly coupled to the canister 106 and indirectly coupled to the dressing 104 through the canister 106. Components may be fluidly coupled to each other to provide a path for transferring fluids (i.e., liquid and/or gas) between the components. In some embodiments, components may be fluidly coupled with the tube 110 and the tube 112, for example. A “tube,” as used herein, broadly refers to a tube, pipe, hose, conduit, or other structure with one or more lumina adapted to convey fluids between two ends. Typically, a tube may be an elongated, cylindrical structure with some flexibility, but the geometry and rigidity may vary. In some embodiments, components may additionally or alternatively be coupled by virtue of physical proximity, being integral to a single structure, or being formed from the same piece of material. Coupling may also include mechanical, thermal, electrical, or chemical coupling (such as a chemical bond) in some contexts.
The fluid mechanics of using a reduced-pressure source to reduce pressure in another component or location, such as within a sealed therapeutic environment, can be mathematically complex. However, the basic principles of fluid mechanics applicable to reduced-pressure therapy are generally well-known to those skilled in the art, and the process of reducing pressure may be described illustratively herein as “delivering,” “distributing,” or “generating” reduced pressure, for example.
In general, exudates and other fluids flow toward lower pressure along a fluid path. This orientation may generally be presumed for purposes of describing various features and components of reduced-pressure therapy systems herein. Thus, the term “downstream” typically implies something in a fluid path relatively closer to a reduced-pressure source, and conversely, the term “upstream” implies something relatively further away from a reduced-pressure source. Similarly, it may be convenient to describe certain features in terms of fluid “inlet” or “outlet” in such a frame of reference. However, the fluid path may also be reversed in some applications (such as by substituting a positive-pressure source for a reduced-pressure source) and this descriptive convention should not be construed as a limiting convention.
“Reduced pressure” generally refers to a pressure less than a local ambient pressure, such as the ambient pressure in a local environment external to a sealed therapeutic environment provided by the dressing 104. In many cases, the local ambient pressure may also be the atmospheric pressure at which a tissue site is located. Alternatively, the pressure may be less than a hydrostatic pressure associated with tissue at the tissue site. Unless otherwise indicated, values of pressure stated herein are gauge pressures. Similarly, references to increases in reduced pressure typically refer to a decrease in absolute pressure, while decreases in reduced pressure typically refer to an increase in absolute pressure.
The dressing 104 generally may include a cover, such as a drape 114, a tissue interface, such as a manifold 116, and a connector, such as an adapter 118. In operation, the manifold 116 may be placed within, over, on, or otherwise proximate to a tissue site, such as the tissue site 102. The drape 114 may be placed over the manifold 116 and sealed to tissue proximate to the tissue site 102. The tissue proximate to the tissue site 102 is often undamaged epidermis peripheral to the tissue site 102. Thus, the dressing 104 can provide a sealed therapeutic environment proximate to the tissue site 102 that may be substantially isolated from the external environment, and the reduced-pressure source 108 can reduce the pressure in the sealed therapeutic environment. Reduced pressure applied across the tissue site 102 through the manifold 116 in the sealed therapeutic environment can induce macrostrain and microstrain in the tissue site 102, as well as remove exudates and other fluids from the tissue site 102. Exudate and other fluid from the tissue site 102 can be collected in the canister 106 and disposed of properly.
The drape 114 may be an example of a sealing member. A sealing member may be constructed from a material that can provide a fluid seal between two components or two environments, such as between a therapeutic environment and a local external environment. The sealing member may be, for example, an impermeable or semi-permeable elastomeric material that can provide a seal adequate to maintain a reduced pressure at a tissue site for a given reduced-pressure source. For semi-permeable materials, the permeability generally should be low enough that a desired reduced pressure may be maintained. An attachment device may be used to attach a sealing member to an attachment surface, such as undamaged epidermis, a gasket, or another sealing member. The attachment device may take many forms. For example, an attachment device may be a medically acceptable, pressure-sensitive adhesive that may extend about a periphery, a portion of, or an entirety of the sealing member. Other example embodiments of an attachment device may include a double-sided tape, paste, hydrocolloid, hydrogel, silicone gel, organogel, or an acrylic adhesive.
The manifold 116 can be generally adapted to contact the tissue site 102. The manifold may be partially or fully in contact with the tissue site 102. If the tissue site 102 is a wound, for example, the manifold 116 may partially or completely fill the wound, or may be placed over the wound. The manifold 116 may take many forms, and may have many sizes, shapes, or thicknesses depending on a variety of factors, such as the type of treatment being implemented or the nature and size of the tissue site 102. For example, the size and shape of the manifold 116 may be adapted to the contours of deep and irregular shaped tissue sites.
More generally, a manifold may be a substance or structure adapted to distribute reduced pressure across a tissue site, remove fluids from across a tissue site, or distribute reduced pressure and remove fluids across a tissue site. In some embodiments, a manifold may also facilitate delivering fluids to a tissue site, if the fluid path is reversed or a secondary fluid path is provided, for example. A manifold may include liquid channels or pathways that distribute fluids provided to and removed from a tissue site around the manifold. In some illustrative embodiments, the liquid channels or pathways may be interconnected to improve distribution or removal of fluids across a tissue site. For example, cellular foam, open-cell foam, porous tissue collections, and other porous material, such as gauze or felted mat, generally include structural elements arranged to form liquid channels. Liquids, gels, and other foams may also include or be cured to include liquid channels.
In one illustrative embodiment, the manifold 116 may be a porous foam material having interconnected cells or pores adapted to distribute reduced pressure across the tissue site 102. The foam material may be either hydrophobic or hydrophilic. In one non-limiting example, the manifold 116 can be an open-cell, reticulated polyurethane foam such as GranuFoam® dressing available from Kinetic Concepts, Inc. of San Antonio, Tex.
In an example in which the manifold 116 may be made from a hydrophilic material, the manifold 116 may also wick fluid away from the tissue site 102, while continuing to distribute reduced pressure to the tissue site 102. The wicking properties of the manifold 116 may draw fluid away from the tissue site 102 by capillary flow or other wicking mechanisms. An example of a hydrophilic foam may be a polyvinyl alcohol, open-cell foam such as V.A.C. WhiteFoam® dressing available from Kinetic Concepts, Inc. of San Antonio, Tex. Other hydrophilic foams may include those made from polyether. Other foams that may exhibit hydrophilic characteristics include hydrophobic foams that have been treated or coated to provide hydrophilicity.
The manifold 116 may further promote granulation at the tissue site 102 if pressure within the sealed therapeutic environment is reduced. For example, any or all of the surfaces of the manifold 116 may have an uneven, coarse, or jagged profile that can induce microstrains and stresses at the tissue site 102 if reduced pressure is applied through the manifold 116.
In one embodiment, the manifold may be constructed from bioresorable materials. Suitable bioresorbable materials may include, without limitation, a polymeric blend of polylactic acid (PLA) and polyglycolic acid (PGA). The polymeric blend may also include without limitation polycarbonates, polyfumarates, and capralactones. The manifold 116 may further serve as a scaffold for new cell-growth, or a scaffold material may be used in conjunction with the manifold 116 to promote cell-growth. A scaffold is generally a substance or structure used to enhance or promote the growth of cells or formation of tissue, such as a three-dimensional porous structure that provides a template for cell growth. Illustrative examples of scaffold materials include calcium phosphate, collagen, PLA/PGA, coral hydroxy apatites, carbonates, or processed allograft materials.
A reduced-pressure source, such as the reduced-pressure source 108, may be a reservoir of air at a reduced pressure, or may be a manually or electrically-powered device that can reduce the pressure in a sealed volume, such as a vacuum pump, a suction pump, a wall suction port available at many healthcare facilities, or a micro-pump, for example. The reduced-pressure source may be housed within or used in conjunction with other components, such as sensors, processing units, alarm indicators, memory, databases, software, display devices, or user interfaces that further facilitate reduced-pressure therapy. While the amount and nature of reduced pressure applied to a tissue site may vary according to therapeutic requirements, the pressure typically ranges between −5 mm Hg (−667 Pa) and −500 mm Hg (−66.7 kPa). Common therapeutic ranges are between −75 mm Hg (−9.9 kPa) and −300 mm Hg (−39.9 kPa).
The canister 106 may be representative of a container, canister, pouch, or other storage component that can be used to manage exudate and other fluid withdrawn from a tissue site. In many environments, a rigid container may be preferred or required for collecting, storing, and disposing of fluid. In other environments, fluid may be properly disposed of without rigid container storage, and a re-usable container could reduce waste and costs associated with reduced-pressure therapy. The canister 106 may be fluidly coupled to the dressing 104 with the tube 110 and fluidly coupled to the reduced-pressure source 108 with the tube 112. The reduced-pressure source 108 supplies reduced pressure to the canister 106 through the tube 112 and to the dressing 104 through the canister 106 and the tube 110. In this manner, the reduced-pressure source 108 may draw fluid, including exudate from the tissue site 102 into the canister 106.
During operation of a reduced-pressure therapy system, a reduced-pressure source may draw fluid from a tissue site into a canister, such as the canister 106. The fluid drawn from a tissue site may have a high content of evaporated liquid, giving the fluid a high relative humidity. If a canister is coupled to a tissue site through a tube, as in therapy system 100, a portion of the evaporated liquid may condense in the tube. This may occur due to the cooler ambient environment surrounding the tube, for example. The fluid, including the condensed liquid in the tube, may be drawn into the canister by the reduced-pressure source.
Once the fluid reaches a canister, additional liquid may condense from the fluid in the canister. Despite the condensation, the fluids in a canister may have a relative humidity as high as about 70%, for example. This relative humidity depends, in part, on the ambient temperature around a canister, the location of the canister, the orientation of the canister, how much liquid may be in the canister, and the type of liquid, including exudate, in the canister.
If a canister is coupled to a reduced-pressure source through another tube, as in therapy system 100, humid fluid may also be drawn from a canister into the tube coupled to the reduced-pressure source. There, further liquid may condense from the fluid in the tube. The condensed liquid in the tube may be drawn into the reduced-pressure source, which may cause the reduced-pressure source to operate improperly or stop functioning altogether.
In other embodiments, a canister and reduced-pressure source may be jointly housed within an integral therapy unit. These units may face problems similar to those described above, as highly humid fluid may be drawn from the canister into the reduced-pressure source.
To address this problem, some canisters may expel the highly humid fluid onto an inside face of the canister before drawing the fluid into a reduced-pressure source. There, the fluid can cool and liquid may condense out of the fluid. The condensation on the inside face of the canister may cause the canister to appear to be leaking. Other canisters expel fluid from the canister into an internal location of a combined canister and reduced-pressure source unit. In these canisters, liquid can condense from the fluids within this structure and can cause the canister to appear to be contaminated. Condensed liquid within the structure may also lead to the growth of flora. Growth of flora within the structure may lead to growth of flora elsewhere in a therapy system that may be detrimental to the health of the person receiving reduced-pressure therapy. Still other canisters may expel the fluid directly into a pump chamber of a reduced-pressure source. Condensed liquid in a pump chamber can cause failure of pump seals, failure of electrical connections within the pump, and a reduced ability to provide reduced-pressure therapy. Systems having a higher fluid flow tolerance may experience a magnification of the problems described above.
As disclosed herein, the therapy system 100 can overcome these shortcomings and others by providing a moisture trap associated with the canister that can reduce the liquid content of fluid leaving the canister 106. For example, in some embodiments of the therapy system 100, a moisture trap may be fluidly coupled between a fluid reservoir of the canister 106 and a reduced-pressure source 108. At least one barrier may be disposed within some embodiments of the moisture trap, providing an indirect fluid path between the fluid reservoir and the reduced-pressure source 108. The barrier preferably comprises a hydrophilic material or a hydrophilic surface. A sump may also be disposed within the moisture trap in fluid communication with the barrier to receive liquid condensed thereon.
As illustrated in the example embodiment of
As shown, the end walls 128 couple to the top and bottom walls 131 and the side walls 129 to form a fluid reservoir 120. The illustrative canister 106 also may include a moisture trap 130. The moisture trap 130 in this example embodiment may be fluidly coupled between the fluid reservoir 120 and the reduced-pressure source 108. As illustrated, for example, the moisture trap 130 can be disposed within the canister 106 proximate to the opening 124 so that fluid flowing from the fluid reservoir 120 passes through the moisture trap 130 before passing through the opening 124.
The moisture trap 130 generally may include a first wall 132, a second wall 134, and at least one fluid barrier, such as a plate 138. As illustrated in
The first wall 132 may have an opening 133 similar to the opening 124, as illustrated in
As illustrated in
The liquid condensed from the fluid flowing through the moisture trap 130 may primarily be water, making materials formed of super absorbent polymers suitable for efficient use as the sump 140. In some embodiments the sump 140 may be sodium polyacrylate. In other embodiments, the sump 140 may be BASF Luquasorb® or Luquafleece® 402C; Technical Absorbents Limited superabsorbent fibers, such as TAL 2327; Texsus spa FP2325; or an isolyser. In still other embodiments, the sump 140 may be an absorbent having carboxymethyl cellulose or alginates.
As illustrated in
Each plate 138 may be in a parallel juxtaposition, for example, each plate 138 may be positioned so that the plate 138 may be parallel to the first wall 132 and to adjacent plates 138. Each plate 138 may also be disposed within the moisture trap 130 and oriented so that a plane in which the plate 138 is disposed may intersect a plane in which the sump 140 is disposed. For example, the plates 138 may all be perpendicular to the sump 140 in some embodiments. In other embodiments, the plates 138 may not be perpendicular to the sump 140, but may also not be parallel to the sump 140. In the illustrated embodiment, the first end of a plate 138 proximate to the first wall 132 may be joined to the second wall 134 so that fluid passes between the second end of the plate 138 and the top wall of the top and bottom walls 131 forming an exterior of the canister 106.
The plate 138 proximate to the opening 124 may also be joined to the second wall 134 so that there may be a gap between the second end of the plate 138 and the top wall 131 forming the exterior of the canister 106. The plate 138 disposed near a center portion of the second wall 134 may be joined to the top wall 131 forming an exterior of the canister 106 so that there may be a gap between the second end of the plate 138 and the second wall 134. In this manner, the plates 138 form an indirect fluid path between the opening 133 and the opening 124. In this context, an “indirect” fluid path may be a fluid path between two locations having at least one change of direction between the two locations. An indirect fluid path may also be referred to as a “tortuous” fluid path, a “labyrinthine” fluid path, or a “convoluted” fluid path.
Additionally or alternatively, the liquid channels 144 may be hydrophobic in some embodiments. Hydrophobic materials may be materials that are treated with or formed from a material that is molecularly repulsive to water. For example, the liquid channels 144 may be formed of a hydrophobic material or have a hydrophobic material disposed thereon, which may facilitate movement of liquid through the liquid channels 144. In the illustrated embodiment, the plate 138 may have a collection end 148 and a drainage end 150. The plate 138 may be oriented within the moisture trap 130 so that the drainage end 150 may be proximate to or adjacent to the sump 140. The liquid channels 144 may form pathways configured to direct condensed liquid toward the drainage end 150 and the sump 140. In the embodiment of
In some embodiments, the barrier in the moisture trap 130 may be a porous plate, mesh, net, or fabric that permits fluid to flow through it. The porous plate, mesh, net, or fabric forms an indirect fluid flow path as the porous plate, mesh, net, or fabric may impede the flow of fluid from the opening 133 to the opening 124. In addition, the porous plate, mesh, net, or fabric may be formed of a plurality of obstructions, such as the fibers of a woven fabric that may cause the fluid to change directions in response to interaction with the obstruction; thus, such obstructions form an indirect fluid path between the opening 133 and the opening 124. For example, if each plate 138 is a porous plate and extends from the top wall 131 to the second wall 134, then fluid can flow through the plate 138 rather than around the plate 138.
The porous plate, mesh, net, or fabric may be formed of a hydrophilic material, or be treated to impart hydrophilic properties to the material. In addition, the liquid channels 144 may be formed on the porous plate, mesh, net, or fabric. In some embodiments, the porous plate, mesh, net, or fabric may have a wax coating to form the liquid channels 144. In other embodiments, the liquid channels 144 may be formed on the porous plate, mesh, net, or fabric versions of the plate 138, for example, the area of the material where the liquid channels 144 are desired could be fused together and treated to impart hydrophobic properties. The porous plate, mesh, net, or fabric versions of the plate 138 may be formed from a woven or non-woven material, a foam, a sintered polymer or formed from a solid piece of material formed to have pores. Nets or meshes may be extruded or expanded to increase the flow area; however, the surface area available for condensation should be maximized. In addition, the porous plate, mesh, net, or fabric versions of the plate 138 may be stacked or layered with additional plates 138.
The plate 138 may be manufactured from a hydrophilic material, for example, and then treated to form the liquid channels 144. Formation of the liquid channels 144 may be accomplished by plasma coating, for example. In plasma coating, plasma may be used to deposit a thin coating of a compound designed to alter the level of hydrophilicity. For example, the plasma coating processes developed by P2i Limited may be used to form the liquid channels 144. In other embodiments, the plate 138 may be formed of a hydrophobic material. The plate 138 may then be treated to form the condensation surface 142. Formation of the condensation surface 142 may be done with a plasma coating process or a wet coating process, for example. In some embodiments, a wet coating process or a chemical vapor deposition process may be used to deposit Parylene to form the condensation surface 142. In other embodiments, a corona or plasma coating process may oxidize the surface of the plate 138 to form the condensation surface 142. Hydak® manufactured by Biocoat, Inc. may also be used to treat the plate 138 to form the condensation surface 142. In some embodiments, the plate 138 may not include the liquid channels 144. In these embodiments, the condensation surface 142 may encompass the entirety of the plate 138. Generally, in embodiments having both the condensation surface 142 and the liquid channels 144, the condensation surface 142 may be greater than or equal to about 80% of the plate 138.
In operation, the reduced-pressure source 108 can supply reduced pressure to the dressing 104 through the canister 106, drawing fluid from the tissue site 102 into the fluid reservoir 120 through the port 122. Fluid may be stored in the fluid reservoir 120 and fluid having evaporated liquid therein may be drawn into the moisture trap 130 through the opening 133. The filter 135 may prevent condensed liquid from passing from the fluid reservoir 120 into the moisture trap 130 so that fluid entering the moisture trap 130 may be composed primarily of gas and evaporated liquid.
The reduced-pressure source 108 can also draw the gas and evaporated liquid through the indirect fluid path provided by the moisture trap 130. Fluid having gas and evaporated liquid may be exposed to a surface of each plate 138 as it moves through the indirect fluid path of the moisture trap 130. For example, as fluid passes through the opening 133, the indirect fluid path formed by the plates 138 can direct fluid toward the top wall 131 forming the exterior of the canister 106 around the second end of the plate 138 and toward the second wall 134 so that the fluid on a first side of the plate 138 flows in an opposite direction from fluid flowing on a second side of the plate 138. In some embodiments, the indirect fluid path can move fluid in opposing directions on opposite sides of each plate 138.
The condensation surface 142 may be a portion of the plate 138 that is attractive to liquid so that liquid evaporated in fluid flowing adjacent to the condensation surface 142 of the plate 138 may be urged to condense from the fluid onto the condensation surface 142. As the gas and evaporated liquid flow across the condensation surfaces 142, the protrusions 146 and the hydrophilic properties of the condensation surfaces 142 can cause the evaporated liquid to condense onto the condensation surfaces 142. The protrusions 146 may aid in condensation by acting as preferential sites for nucleation that condenses liquid from the fluid passing by the condensation surface 142. The protrusions 146 may also aid in moving liquid condensed onto the condensation surface 142 toward the liquid channels 144. As liquid is condensed, the liquid may be urged toward the sump 140 by the liquid channels 144. If the liquid reaches the sump 140, the liquid may be trapped by the sump 140. In this manner, the liquid content of fluid leaving the canister 106 may be reduced.
The illustrative embodiment of the moisture trap 330 also may include a fluid inlet 333 and a fluid outlet 324. The fluid inlet 333 may be disposed proximate to the cylindrical side wall 306 and a peripheral portion of the bottom wall 304. The fluid outlet 324 may be disposed proximate to a center portion of the top wall 302 and be may generally be aligned with an axis of the moisture trap 330. Both the fluid inlet 333 and the fluid outlet 324 may be cylindrical bodies configured to be fluidly coupled to a conduit so that the moisture trap 330 may be disposed in a fluid path between a fluid reservoir and a reduced-pressure source. For example, the moisture trap 330 may be fluidly coupled between the fluid reservoir 120 of the canister 106 and the reduced-pressure source 108 of
The moisture trap 330 also may include a sump 340, which may be similar in many respects to the sump 140. In the illustrative embodiment of
Liquid condensed from fluid flowing through the moisture trap 330 may primarily be water, making materials formed of super-absorbent polymers suitable for efficient use as the sump 340. In some embodiments the sump 340 may be sodium polyacrylate. In other embodiments, the sump 340 may be BASF Luquasorb® or Luquafleece® 402C; Technical Absorbents Limited superabsorbent fibers, such as TAL 2327; Texsus spa FP2325; or an isolyser. In still other embodiments, the sump 340 may be an absorbent having carboxymethyl cellulose or alginates.
The moisture trap 330 also may include a fluid barrier, such as a spiral barrier 338. The spiral barrier 338 may be similar to the plate 138 in some respects. The spiral barrier 338 may be an Archimedean spiral having a first end 310, a second end 312, and opposing lateral edges 314, 316. The spiral barrier 338 may have other spiral shapes such as Cornu, Fermat, hyperbolic, lituus, or logarithmic spirals, for example. The spiral barrier 338 may be disposed within the interior 308 so that the first end 310 may be proximate to the fluid inlet 333 and the second end 312 may be proximate to the fluid outlet 324. In the illustrated embodiment, the first end 310 may be adjacent to the cylindrical side wall 306 so that fluid may not flow between the first end 310 and the cylindrical side wall 306. In other embodiments, the first end 310 may be proximate to the cylindrical side wall 306 and allows fluid flow between the first end 310 and the cylindrical side wall 306. The opposing lateral edges 314, 316 may be coupled to the top wall 302 and the bottom wall 304, respectively, to prevent fluid communication between the opposing lateral edges 314, 316 and the top wall 302 and the bottom wall 304.
The spiral barrier 338 may also include condensation surfaces and liquid channels similar to the condensation surfaces 142 and the liquid channels 144 of the plate 138. The condensation surfaces may operate similar to the condensation surface 142 and the liquid channels may direct fluid to the sump 340 similar to the liquid channels 144. The condensation surfaces and the liquid channels may also be formed in a manner similar to the condensation surface 142 and the liquid channels 144.
The spiral barrier 338 may be a single member formed to have the spiral shape. The spiral barrier 338 may be manufactured by rolling a strip of a plate-like material to form the desired shape, for example. In some embodiments, a strip of material may be bent to form the desired shape. In still other embodiments, the spiral barrier 338 may be formed of multiple members joined to form the spiral shape.
In operation, fluid may enter the moisture trap 330 through the fluid inlet 333 proximate to the first end 310 of the spiral barrier 338, and may flow adjacent to the surface of the spiral barrier 338. The curve of the spiral barrier 338 may be adapted to direct fluid along a spiral path toward the second end 312 of the spiral barrier 338 proximate to the fluid outlet 324. In this manner, the spiral barrier 338 forms an indirect fluid path between the fluid inlet 333 and the fluid outlet 324 by changing the direction of the fluid as the fluid flows between the fluid inlet 333 and the fluid outlet 324. In some embodiments, as fluid flows adjacent to the spiral barrier 338, hydrophilic condensation surfaces may cause liquid to condense from the fluid onto the surface of the spiral barrier 338.
The first wall 432 may extend from the second wall 434 toward the top wall 431 of the canister 406 a portion of the distance between the second wall 434 and the top wall 431 of the canister 406. This may form an opening 433 that permits fluid communication between the moisture trap 430 and a fluid reservoir of the canister 406. In some embodiments, the first wall 432 may join the top wall 431 of the canister 406 and the opening 433 may be formed in the first wall 432 similar to the first wall 132 and the opening 133. A filter may be disposed within the opening 433. In the example embodiment of
The moisture trap 430 may also include a sump 440. In the illustrated embodiment, the sump 440 may be disposed adjacent to the second wall 434 and perpendicular to the first wall 432. The sump 440 may include an absorbent layer having a thickness less than the height of the first wall 432, and may be coextensive with the second wall 434 in some embodiments. In some embodiments, the thickness of the absorbent layer may vary as needed for the particular application of the moisture trap 430. In some embodiments, the sump 440 may extend only a portion of the second wall 434 of the moisture trap 430 to allow the sump 440 to expand as the sump 440 receives fluid, for example. The sump 440 can be fluidly isolated from the fluid reservoir in some embodiments so that liquid in the fluid reservoir may not interact with the sump 440.
Liquid condensed from the fluid flowing through the moisture trap 430 may primarily be water, making materials formed of super absorbent polymers suitable for efficient use as the sump 440. In some embodiments the sump 440 may be sodium polyacrylate. In other embodiments, the sump 440 may be BASF Luquasorb® or Luquafleece® 402C; Technical Absorbents Limited superabsorbent fibers, such as TAL 2327; Texsus spa FP2325; or an isolyser. In still other embodiments, the sump 440 may be an absorbent having carboxymethyl cellulose or alginates.
As illustrated in
Each cell wall 452 may include a plurality of perforations 462. The perforations 462 may extend through the cell wall 452 so that fluid may communicate through the cell wall 452. In some embodiments, the perforations 462 may permit fluid communication between the channel 460 and an ambient environment, for example a fluid reservoir of the canister 406. The perforations 462 may also permit fluid communication between the channels 460 of adjacent cells 450 having an interconnected cell wall 452. In the illustrated embodiment, each cell 450 may have a distance between parallel sides, that is, across the flats, of about 6 mm. The size of the cells 450 may be reduced to increase the available surface area provided the by cell walls 452, thus increasing the ability of the cells 450 to cause condensation. In addition, the size of the cells 450 may be increased to reduce the flow restriction through the moisture trap 430, if desired. The cells 450 may be formed of a thermoplastic and may have hydrophilic properties. In some embodiments, the cells 450 may be formed of a material such as those manufactured by Baltex, Plascore, Inc., or Hexacor Limited. In some embodiments, these materials may be referred to as a 3-D fabric. 3-D fabrics may be materials having the flexibility associated with fabric while having length, width, and depth. Some 3-D fabrics may be formed similar to the array 438 described above. Other 3-D fabrics may be formed having two layers of woven material joined by a plurality of fibers. The material may also be treated similar to the plate 138 to vary the hydrophilicty of the material as desired for the particular application of the array 438.
As shown in
In operation, the reduced-pressure source 108 can supply reduced pressure to the dressing 104 through the canister 406, drawing fluid from the tissue site 102 into the canister 106. Fluid may be stored in a fluid reservoir of the canister 106 and fluid having evaporated liquid therein may be drawn into the moisture trap 430 through the opening 433. The reduced-pressure source 108 can also draw the gas and evaporated liquid through an indirect fluid path formed by the array 438. As fluid passes through a perforation 462 in a first cell wall 452 of a cell 450 the fluid may change direction to reach the fluid outlet 424. If fluid to passes through a perforation 462 in a first cell wall 452 and not change direction, the fluid flow should eventually abut the top wall 431, the side walls of the canister 406, or the second wall 434 before reaching the fluid outlet 424. The top wall 431 and the side walls of the canister 406 or the second wall 434 can cause a change in the direction of the fluid flow. In this manner, the plurality of cells 450 can form an indirect fluid path. The array 438 can provide a large condensation area by increasing the surface area that the fluid may contact as it passes through the moisture trap 430. As gas and evaporated liquid flow across the surfaces of the cells 450, evaporated liquid can condense onto the cell walls 452. As liquid is condensed, the liquid may be urged toward the sump 440 by the channels 460. If liquid reaches the sump 440, the liquid may be trapped by the sump 440. In this manner, the moisture content of fluid leaving the canister 406 may be reduced. In some embodiments, the sump 440 and the array 438 may be joined to form a multi-function fluid management laminate.
As illustrated, the example embodiment of the moisture trap 530 also may include a sump 540. The sump 540 may be disposed adjacent to the second wall 534 perpendicular to the first wall 532. The sump 540 may include a layer of absorbent material having a thickness less than the height of the first wall 532, and may be coextensive with the second wall 534. In some embodiments, the thickness of the absorbent material may vary as needed for the particular application of the moisture trap 530. In some embodiments, the sump 540 may not be coextensive with the second wall 534 of the moisture trap 530 to allow the sump 540 to expand as the sump 540 receives liquid, for example. In the illustrated embodiment, the sump 540 may be fluidly isolated from a fluid reservoir so that liquids in the fluid reservoir may not interact with the sump 540. The sump 540 may be an absorbent material disposed within the moisture trap 530 to collect liquid condensed from fluid flowing through the moisture trap 530.
Liquid condensed from fluid flowing through the moisture trap 530 may primarily be water, making materials formed of super-absorbent polymers suitable for efficient use as the sump 540. In some embodiments the sump 540 may be sodium polyacrylate. In other embodiments, the sump 540 may be BASF Luquasorb® or Luquafleece® 402C; Technical Absorbents Limited superabsorbent fibers, such as TAL 2327; Texsus spa FP2325; or an isolyser. In still other embodiments, the sump 540 may be an absorbent having carboxymethyl cellulose or alginates.
In operation, fluid can flow through the opening 533, encountering the mesh layer 554. The mesh layer 554 may be disposed in the fluid path between the opening 533 and the fluid outlet 524, causing fluid to flow in an indirect fluid path. Fibers forming the mesh layer 554 may cause fluid to make numerous changes of direction as fluid flows through the mesh layer 554. As fluid interacts with the mesh layer 554, hydrophilic properties of the mesh layer 554 may cause liquid to condense from the fluid. The mesh layer 554 may direct liquid along fibers of the mesh layer 554 into the lower layer 552. The lower layer 552 may wick liquid into the sump 540, where liquid can be stored. Fluid that may flow through the upper layer 550 may be directed into the mesh layer 554, where the mesh layer 554 may then cause liquid to condense from the fluid as described above.
The systems and methods described herein may provide significant advantages, some of which have already been mentioned. For example, the illustrative moisture traps can significantly reduce liquid content of fluid that exits a canister. The moisture traps may also prevent condensate from appearing in places where liquid should not be and prevent condensed liquid from providing a false perception that the device or canister may have been damaged or may be leaking. The moisture traps may also reduce the maintenance and service costs of a device. In many applications, the moisture traps can also make efficient use of a sump having a super-absorbent, as a super-absorbent sump can absorb more pure water condensed from fluid. In some embodiments, the moisture traps may also trap volatile organic compounds and other airborne particulates as liquid condenses. Some embodiments of the moisture traps may also help to dispose of fluidly contaminated components. Some embodiments of the moisture traps can be incorporated into a canister with minimal cost and may be retrofitted to other standard (Bemis type) canisters. Still further, some embodiments of the moisture traps may be replaceable with each canister.
It should be apparent from the foregoing that an invention having significant advantages has been described. While shown in only a few forms, the systems and methods illustrated are susceptible to various changes and modifications without departing from the spirit thereof.
Although certain illustrative, non-limiting embodiments have been presented, it should be understood that various changes, substitutions, permutations, and alterations can be made without departing from the scope the appended claims. It will be appreciated that any feature that is described in connection to any one embodiment may also be applicable to any other embodiment.
It will be understood that the benefits and advantages described above may relate to one embodiment or may relate to several embodiments. The operations described herein may be carried out in any suitable order, or simultaneously where appropriate.
Where appropriate, features of any of the embodiments described above may be combined with features of any of the other embodiments described to form further examples having comparable or different properties and addressing the same or different problems.
It will be understood that the above description of preferred embodiments is given by way of example only and that various modifications may be made by those skilled in the art. The above specification, examples and data provide a complete description of the structure and use of exemplary embodiments of the invention. Although various embodiments of the invention have been described above with a certain degree of particularity, or with reference to one or more individual embodiments, those skilled in the art could make numerous alterations to the disclosed embodiments without departing from the scope of the claims.
This application is a continuation of U.S. patent application Ser. No. 15/497,892, filed Apr. 26, 2017, which is a continuation of U.S. patent application Ser. No. 14/186,808, now U.S. Pat. No. 9,669,139, filed Feb. 21, 2014, which claims the benefit, under 35 USC 119(e), of the filing of U.S. Provisional Patent Application No. 61/784,734, entitled “Wound Fluid Collection Canister with Integrated Condensation Inhibitor,” filed Mar. 14, 2013, which is incorporated herein by reference for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
1355846 | Rannells | Oct 1920 | A |
2402140 | Heintzelman | Jun 1946 | A |
2547758 | Keeling | Apr 1951 | A |
2632443 | Lesher | Mar 1953 | A |
2682873 | Evans et al. | Jul 1954 | A |
2910763 | Lauterbach | Nov 1959 | A |
2969057 | Simmons | Jan 1961 | A |
3066672 | Crosby, Jr. et al. | Dec 1962 | A |
3226098 | Shryock | Dec 1965 | A |
3367332 | Groves | Feb 1968 | A |
3520300 | Flower, Jr. | Jul 1970 | A |
3568675 | Harvey | Mar 1971 | A |
3648692 | Wheeler | Mar 1972 | A |
3682180 | McFarlane | Aug 1972 | A |
3739553 | Aine | Jun 1973 | A |
3826254 | Mellor | Jul 1974 | A |
3892550 | Riis | Jul 1975 | A |
4080970 | Miller | Mar 1978 | A |
4096853 | Weigand | Jun 1978 | A |
4139004 | Gonzalez, Jr. | Feb 1979 | A |
4165748 | Johnson | Aug 1979 | A |
4184510 | Murry et al. | Jan 1980 | A |
4202778 | Middelbeek | May 1980 | A |
4233969 | Lock et al. | Nov 1980 | A |
4245630 | Lloyd et al. | Jan 1981 | A |
4256109 | Nichols | Mar 1981 | A |
4261363 | Russo | Apr 1981 | A |
4275721 | Olson | Jun 1981 | A |
4284079 | Mair | Aug 1981 | A |
4297995 | Golub | Nov 1981 | A |
4314605 | Sumitomo | Feb 1982 | A |
4333468 | Geist | Jun 1982 | A |
4373519 | Errede et al. | Feb 1983 | A |
4382441 | Svedman | May 1983 | A |
4392853 | Muto | Jul 1983 | A |
4392858 | George et al. | Jul 1983 | A |
4419097 | Rowland | Dec 1983 | A |
4465485 | Kashmer et al. | Aug 1984 | A |
4475909 | Eisenberg | Oct 1984 | A |
4480638 | Schmid | Nov 1984 | A |
4525166 | Leclerc | Jun 1985 | A |
4525374 | Vaillancourt | Jun 1985 | A |
4540412 | Van Overloop | Sep 1985 | A |
4543100 | Brodsky | Sep 1985 | A |
4548202 | Duncan | Oct 1985 | A |
4551139 | Plaas et al. | Nov 1985 | A |
4569348 | Hasslinger | Feb 1986 | A |
4605399 | Weston et al. | Aug 1986 | A |
4608041 | Nielsen | Aug 1986 | A |
4640688 | Hauser | Feb 1987 | A |
4655754 | Richmond et al. | Apr 1987 | A |
4664662 | Webster | May 1987 | A |
4710165 | McNeil et al. | Dec 1987 | A |
4733659 | Edenbaum et al. | Mar 1988 | A |
4743232 | Kruger | May 1988 | A |
4758220 | Sundblom et al. | Jul 1988 | A |
4787888 | Fox | Nov 1988 | A |
4818257 | Kennedy et al. | Apr 1989 | A |
4826494 | Richmond et al. | May 1989 | A |
4838883 | Matsuura | Jun 1989 | A |
4840187 | Brazier | Jun 1989 | A |
4863449 | Therriault et al. | Sep 1989 | A |
4872450 | Austad | Oct 1989 | A |
4878901 | Sachse | Nov 1989 | A |
4897081 | Poirier et al. | Jan 1990 | A |
4906233 | Moriuchi et al. | Mar 1990 | A |
4906240 | Reed et al. | Mar 1990 | A |
4919654 | Kalt | Apr 1990 | A |
4941882 | Ward et al. | Jul 1990 | A |
4953565 | Tachibana et al. | Sep 1990 | A |
4969880 | Zamierowski | Nov 1990 | A |
4985019 | Michelson | Jan 1991 | A |
5000768 | Hwang | Mar 1991 | A |
5037397 | Kalt et al. | Aug 1991 | A |
5078603 | Cohen | Jan 1992 | A |
5086170 | Luheshi et al. | Feb 1992 | A |
5092858 | Benson et al. | Mar 1992 | A |
5100396 | Zamierowski | Mar 1992 | A |
5134994 | Say | Aug 1992 | A |
5149331 | Ferdman et al. | Sep 1992 | A |
5167613 | Karami et al. | Dec 1992 | A |
5176663 | Svedman et al. | Jan 1993 | A |
5215522 | Page et al. | Jun 1993 | A |
5232453 | Plass et al. | Aug 1993 | A |
5261893 | Zamierowski | Nov 1993 | A |
5278100 | Doan et al. | Jan 1994 | A |
5279550 | Habib et al. | Jan 1994 | A |
5298015 | Komatsuzaki et al. | Mar 1994 | A |
5342376 | Ruff | Aug 1994 | A |
5344415 | DeBusk et al. | Sep 1994 | A |
5358494 | Svedman | Oct 1994 | A |
5437622 | Carion | Aug 1995 | A |
5437651 | Todd et al. | Aug 1995 | A |
5460147 | Bohl | Oct 1995 | A |
5527293 | Zamierowski | Jun 1996 | A |
5549584 | Gross | Aug 1996 | A |
5556375 | Ewall | Sep 1996 | A |
5587053 | Keith | Dec 1996 | A |
5607388 | Ewall | Mar 1997 | A |
5636643 | Argenta et al. | Jun 1997 | A |
5645081 | Argenta et al. | Jul 1997 | A |
5882386 | McAferty et al. | Mar 1999 | A |
5985004 | Boyd | Nov 1999 | A |
6071267 | Zamierowski | Jun 2000 | A |
6135116 | Vogel et al. | Oct 2000 | A |
6241747 | Ruff | Jun 2001 | B1 |
6267804 | Marlowe | Jul 2001 | B1 |
6286589 | Uehara | Sep 2001 | B1 |
6287316 | Agarwal et al. | Sep 2001 | B1 |
6345623 | Heaton et al. | Feb 2002 | B1 |
6488643 | Tumey et al. | Dec 2002 | B1 |
6493568 | Bell et al. | Dec 2002 | B1 |
6553998 | Heaton et al. | Apr 2003 | B2 |
6814079 | Heaton et al. | Nov 2004 | B2 |
7846141 | Weston | Dec 2010 | B2 |
8002712 | Meka et al. | Aug 2011 | B2 |
8062273 | Weston | Nov 2011 | B2 |
8216198 | Heagle et al. | Jul 2012 | B2 |
8251979 | Malhi | Aug 2012 | B2 |
8257327 | Blott et al. | Sep 2012 | B2 |
8398614 | Blott et al. | Mar 2013 | B2 |
8449509 | Weston | May 2013 | B2 |
8529548 | Blott et al. | Sep 2013 | B2 |
8535296 | Blott et al. | Sep 2013 | B2 |
8551060 | Schuessler et al. | Oct 2013 | B2 |
8568386 | Malhi | Oct 2013 | B2 |
8679081 | Heagle et al. | Mar 2014 | B2 |
8834451 | Blott et al. | Sep 2014 | B2 |
8926592 | Blott et al. | Jan 2015 | B2 |
9017302 | Vitaris et al. | Apr 2015 | B2 |
9198801 | Weston | Dec 2015 | B2 |
9211365 | Weston | Dec 2015 | B2 |
9289542 | Blott et al. | Mar 2016 | B2 |
20010003892 | Rikyuu et al. | Jun 2001 | A1 |
20020020182 | Hauser et al. | Feb 2002 | A1 |
20020077661 | Saadat | Jun 2002 | A1 |
20020115951 | Norstrem et al. | Aug 2002 | A1 |
20020120185 | Johnson | Aug 2002 | A1 |
20020143286 | Tumey | Oct 2002 | A1 |
20020144600 | TeGrotenhuis et al. | Oct 2002 | A1 |
20030037730 | Yamasaki et al. | Feb 2003 | A1 |
20030150198 | Illingworth et al. | Aug 2003 | A1 |
20030150483 | Max | Aug 2003 | A1 |
20030163101 | Say | Aug 2003 | A1 |
20040109981 | Lawrence et al. | Jun 2004 | A1 |
20040232052 | Call et al. | Nov 2004 | A1 |
20050000199 | Carter | Jan 2005 | A1 |
20050161030 | Roberts et al. | Jul 2005 | A1 |
20050251099 | Drogue et al. | Nov 2005 | A1 |
20060064991 | Kozak et al. | Mar 2006 | A1 |
20060112709 | Boyle | Jun 2006 | A1 |
20070295315 | Guerry et al. | Dec 2007 | A1 |
20080034966 | Kesten et al. | Feb 2008 | A1 |
20080149082 | Heed | Jun 2008 | A1 |
20080190853 | Toma | Aug 2008 | A1 |
20080210279 | Hildenbrand | Sep 2008 | A1 |
20080236116 | Kawasaki | Oct 2008 | A1 |
20090071189 | Martins et al. | Mar 2009 | A1 |
20090077992 | Anderson et al. | Mar 2009 | A1 |
20090117428 | Chen | May 2009 | A1 |
20090126575 | Son et al. | May 2009 | A1 |
20090221990 | Jaeb et al. | Sep 2009 | A1 |
20100126479 | Shieh et al. | May 2010 | A1 |
20100293905 | Lin et al. | Nov 2010 | A1 |
20110167774 | Herman et al. | Jul 2011 | A1 |
20110197764 | Ardizzone | Aug 2011 | A1 |
20110288512 | Locke et al. | Nov 2011 | A1 |
20120132075 | Jarrier et al. | May 2012 | A1 |
20130170142 | Weaver, Jr. et al. | Jul 2013 | A1 |
20130206577 | Bauer | Aug 2013 | A1 |
20130251948 | Lyons et al. | Sep 2013 | A1 |
20130276416 | Schook | Oct 2013 | A1 |
20130295315 | Durdag et al. | Nov 2013 | A1 |
20140109533 | Horiuchi | Apr 2014 | A1 |
20140163491 | Schuessler et al. | Jun 2014 | A1 |
20140182456 | Chou et al. | Jul 2014 | A1 |
20150080788 | Blott et al. | Mar 2015 | A1 |
20170036149 | Barley et al. | Feb 2017 | A1 |
Number | Date | Country |
---|---|---|
550575 | Mar 1986 | AU |
745271 | Mar 2002 | AU |
755496 | Dec 2002 | AU |
2005436 | Jun 1990 | CA |
26 40 413 | Mar 1978 | DE |
43 06 478 | Sep 1994 | DE |
29 504 378 | Sep 1995 | DE |
0100148 | Feb 1984 | EP |
0117632 | Sep 1984 | EP |
0161865 | Nov 1985 | EP |
0358302 | Mar 1990 | EP |
1018967 | Jul 2000 | EP |
692578 | Jun 1953 | GB |
2195255 | Apr 1988 | GB |
2 197 789 | Jun 1988 | GB |
2 220 357 | Jan 1990 | GB |
2 235 877 | Mar 1991 | GB |
2 329 127 | Mar 1999 | GB |
2 333 965 | Aug 1999 | GB |
4129536 | Aug 2008 | JP |
71559 | Apr 2002 | SG |
8002182 | Oct 1980 | WO |
8704626 | Aug 1987 | WO |
90010424 | Sep 1990 | WO |
93009727 | May 1993 | WO |
9420041 | Sep 1994 | WO |
9605873 | Feb 1996 | WO |
9718007 | May 1997 | WO |
9913793 | Mar 1999 | WO |
Entry |
---|
Louis C. Argenta, MD and Michael J. Morykwas, PHD; Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Clinical Experience; Annals of Plastic Surgery; vol. 38, No. 6, Jun. 1997; pp. 563-576. |
Susan Mendez-Eatmen, RN; “When wounds Won't Heal” RN Jan. 1998, vol. 61 (1); Medical Economics Company, Inc., Montvale, NJ, USA; pp. 20-24. |
James H. Blackburn II, MD et al.: Negative-Pressure Dressings as a Bolster for Skin Grafts; Annals of Plastic Surgery, vol. 40, No. 5, May 1998, pp. 453-457; Lippincott Williams & Wilkins, Inc., Philidelphia, PA, USA. |
John Masters; “Reliable, Inexpensive and Simple Suction Dressings”; Letter to the Editor, British Journal of Plastic Surgery, 1998, vol. 51 (3), p. 267; Elsevier Science/The British Association of Plastic Surgeons, UK. |
S.E. Greer, et al. “The Use of Subatmospheric Pressure Dressing Therapy to Close Lymphocutaneous Fistulas of the Groin” British Journal of Plastic Surgery (2000), 53, pp. 484-487. |
George V. Letsou, MD., et al; “Stimulation of Adenylate Cyclase Activity in Cultured Endothelial Cells Subjected to Cyclic Stretch”; Journal of Cardiovascular Surgery, 31, 1990, pp. 634-639. |
Orringer, Jay, et al; “Management of Wounds in Patients with Complex Enterocutaneous Fistulas”; Surgery, Gynecology & Obstetrics, Jul. 1987, vol. 165, pp. 79-80. |
International Search Report for PCT International Application PCT/GB95/01983; dated Nov. 23, 1995. |
PCT International Search Report for PCT International Application PCT/GB98/02713; dated Jan. 8, 1999. |
PCT Written Opinion; PCT International Application PCT/GB98/02713; dated Jun. 8, 1999. |
PCT International Examination and Search Report, PCT International Application PCT/GB96/02802; dated Jan. 15, 1998 & Apr. 29, 1997. |
PCT Written Opinion, PCT International Application PCT/GB96/02802; dated Sep. 3, 1997. |
Dattilo, Philip P., Jr., et al; “Medical Textiles: Application of an Absorbable Barbed Bi-directional Surgical Suture”; Journal of Textile and Apparel, Technology and Management, vol. 2, Issue 2, Spring 2002, pp. 1-5. |
Kostyuchenok, B.M., et al; “Vacuum Treatment in the Surgical Management of Purulent Wounds”; Vestnik Khirurgi, Sep. 1986, pp. 18-21 and 6 page English translation thereof. |
Davydov, Yu. A., et al; “Vacuum Therapy in the Treatment of Purulent Lactation Mastitis”; Vestnik Khirurgi, May 14, 1986, pp. 66-70, and 9 page English translation thereof. |
Yusupov. Yu.N., et al; “Active Wound Drainage”, Vestnki Khirurgi, vol. 138, Issue 4, 1987, and 7 page English translation thereof. |
Davydov, Yu.A., et al.; “Bacteriological and Cytological Assessment of Vacuum Therapy for Purulent Wounds”; Vestnik Khirugi, Oct. 1988, pp. 48-52, and 8 page English translation thereof. |
Davydov, Yu.A., et al.; “Concepts for the Clinical-Biological Management of the Wound Process in the Treatment of Purulent Wounds by Means of Vacuum Therapy”; Vestnik Khirurgi, Jul. 7, 1980, pp. 132-136, and 8 page English translation thereof. |
Chariker, Mark E., M.D., et al; “Effective Management of incisional and cutaneous fistulae with closed suction wound drainage”; Contemporary Surgery, vol. 34, Jun. 1989, pp. 59-63. |
Egnell Minor, Instruction Book, First Edition, 300 7502, Feb. 1975, pp. 24. |
Egnell Minor: Addition to the Users Manual Concerning Overflow Protection—Concerns all Egnell Pumps, Feb. 3, 1983, pp. 2. |
Svedman, P.: “Irrigation Treatment of Leg Ulcers”, The Lancet, Sep. 3, 1983, pp. 532-534. |
Chinn, Steven D. et al.: “Closed Wound Suction Drainage”, The Journal of Foot Surgery, vol. 24, No. 1, 1985, pp. 76-81. |
Arnljots, Björn et al.: “Irrigation Treatment in Split-Thickness Skin Grafting of Intractable Leg Ulcers”, Scand J. Plast Reconstr. Surg., No. 19, 1985, pp. 211-213. |
Svedman, P.: “A Dressing Allowing Continuous Treatment of a Biosurface”, IRCS Medical Science: Biomedical Technology, Clinical Medicine, Surgery and Transplantation, vol. 7, 1979, p. 221. |
Svedman, P. et al: “A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous of Intermittent Irrigation”, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133. |
N.A. Bagautdinov, “Variant of External Vacuum Aspiration in the Treatment of Purulent Diseases of Soft Tissues,” Current Problems in Modern Clinical Surgery: Interdepartmental Collection, edited by V. Ye Volkov et al. (Chuvashia State University, Cheboksary, U.S.S.R. 1986); pp. 94-96 (certified translation). |
K.F. Jeter, T.E. Tintle, and M. Chariker, “Managing Draining Wounds and Fistulae: New and Established Methods,” Chronic Wound Care, edited by D. Krasner (Health Management Publications, Inc., King of Prussia, PA 1990), pp. 240-246. |
G. {circumflex over (Z)}ivadinovi?, V. ?uki?, {circumflex over (Z)}. Maksimovi?, ?. Radak, and P. Peŝka, “Vacuum Therapy in the Treatment of Peripheral Blood Vessels,” Timok Medical Journal 11 (1986), pp. 161-164 (certified translation). |
F.E. Johnson, “An Improved Technique for Skin Graft Placement Using a Suction Drain,” Surgery, Gynecology, and Obstetrics 159 (1984), pp. 584-585. |
A.A. Safronov, Dissertation Abstract, Vacuum Therapy of Trophic Ulcers of the Lower Leg with Simultaneous Autoplasty of the Skin (Central Scientific Research Institute of Traumatology and Orthopedics, Moscow, U.S.S.R. 1967) (certified translation). |
M. Schein, R. Saadia, J.R. Jamieson, and G.A.G. Decker, “The ‘Sandwich Technique’ in the Management of the Open Abdomen,” British Journal of Surgery 73 (1986), pp. 369-370. |
D.E. Tribble, An Improved Sump Drain-Irrigation Device of Simple Construction, Archives of Surgery 105 (1972) pp. 511-513. |
M.J. Morykwas, L.C. Argenta, E.I. Shelton-Brown, and W. McGuirt, “Vacuum-Assisted Closure: A New Method for Wound Control and Treatment: Animal Studies and Basic Foundation,” Annals of Plastic Surgery 38 (1997), pp. 553-562 (Morykwas I). |
C.E. Tennants, “The Use of Hypermia in the Postoperative Treatment of Lesions of the Extremities and Thorax,” Journal of the American Medical Association 64 (1915), pp. 1548-1549. |
Selections from W. Meyer and V. Schmieden, Bier's Hyperemic Treatment in Surgery, Medicine, and the Specialties: A Manual of Its Practical Application, (W.B. Saunders Co., Philadelphia, PA 1909), pp. 17-25, 44-64, 90-96,167-170, and 210-211. |
V.A. Solovev et al., Guidelines, The Method of Treatment of Immature External Fistulas in the Upper Gastrointestinal Tract, editor-in-chief Prov. V.I. Parahonyak (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1987) (“Solovev Guidelines”). |
V.A. Kuznetsov & N.a. Bagautdinov, “Vacuum and Vacuum-Sorption Treatment of Open Septic Wounds,” in II All-Union Conference on Wounds and Wound Infections: Presentation Abstracts, edited by B.M. Kostyuchenok et al. (Moscow, U.S.S.R. Oct. 28-29, 1986) pp. 91-92 (“Bagautdinov II”). |
V.A. Solovev, Dissertation Abstract, Treatment and Prevention of Suture Failures after Gastric Resection (S.M. Kirov Gorky State Medical Institute, Gorky, U.S.S.R. 1988) (“Solovev Abstract”). |
V.A.C. ® Therapy Clinical Guidelines: A Reference Source for Clinicians; Jul. 2007. |
Number | Date | Country | |
---|---|---|---|
20200171220 A1 | Jun 2020 | US |
Number | Date | Country | |
---|---|---|---|
61784734 | Mar 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15497892 | Apr 2017 | US |
Child | 16781552 | US | |
Parent | 14186808 | Feb 2014 | US |
Child | 15497892 | US |